In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Guidance programme

Guidance programme

HealthTech approach

HealthTech approach

Advice programme

Area of interest

Showing 326 to 350 of 386

TitleTypeExpected publication date
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]Technology appraisal guidance
Spesolimab for preventing generalised pustular psoriasis flares in people 12 years and over [TSID12086]Technology appraisal guidanceTBC
Sugemalimab with chemotherapy for untreated advanced non-small-cell lung cancer [ID6758]Technology appraisal guidanceTBC
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]Technology appraisal guidanceTBC
Surgical mesh for treatment of non-primary ventral herniasHealthTech guidanceTBC
Surgical mesh for treatment of primary ventral herniasHealth technology evaluation
Surgical vessel sealing systems (MT798)Medical technologies guidanceTBC
Suspected cancer updateQuality standardTBC
Suspected sepsis in pregnancy: recognition, diagnosis and early managementNICE guideline
Suspected sepsis in under 16s: recognition, diagnosis and early managementNICE guideline
Suspected sepsis: recognition, diagnosis and early managementNICE guidelineTBC
Suspected sepsis: recognition, diagnosis and early management - procalcitonin testingNICE guideline
Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [ID6568]Technology appraisal guidance
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6413]Technology appraisal guidance
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]Technology appraisal guidanceTBC
Tarlatamab for treating extensive stage small-cell lung cancer that has progressed after platinum-based chemotherapy [ID6617]Technology appraisal guidance
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women [ID1401]Technology appraisal guidanceTBC
Technologies for the rapid diagnosis of endometriosis: early use assessmentHealth technology evaluation
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]Technology appraisal guidanceTBC
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]Technology appraisal guidanceTBC
Teprotumumab for treating thyroid eye disease (deferred appraisal of D1) [ID6756]Technology appraisal guidanceTBC
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [ID6379]Technology appraisal guidance
Third molars (impacted) - prophylactic removal [ID898]Technology appraisal guidanceTBC
Tiragolumab with atezolizumab and bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [TSID12238]Technology appraisal guidanceTBC
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All